Theoretical predictions of drug absorption in drug discovery and development

Clinical Pharmacokinetics

Volumn 41, Issue 11, 2002, Pages 877-899

  Stenberg, Patric ^a   Bergström, Christel A S ^a   Luthman, Kristina ^b   Artursson, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GANCICLOVIR; LEVODOPA; VALGANCICLOVIR; ZIDOVUDINE;

ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; INTESTINE MUCOSA PERMEABILITY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXICITY; TRANSCYTOSIS;

EID: 0036380244     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241110-00005     Document Type: Review

References (185)

1. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-96
2. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997; 2: 436-44
3. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000; 89: 145-54
4. Arlington S. Pharma 2005. Pharm Exec 2000; 20: 74-84
5. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25
6. Testa B, Caldwell J. Prodrugs revisited: the "ad hoc" approach as a complement to ligand design. Med Res Rev 1996; 16: 233-41
7. Rowland M, Tozer TN. Clinical pharmacokinetics. 2nd ed. Malvern: Lea and Febiger, 1989
8. Chiou WL. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology. J Pharmacokinet Pharmacodyn 2001; 28: 3-6
9. Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20
10. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996; 13: 1795-8
11. Norris DA, Leesman GD, Sinko PJ, et al. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 2000; 65: 55-62
12. SimulationsPlus Inc. GastroPlus™. Available from URL: http://www.simulationsplus.com/ [Accessed 2002 Jul 19]
13. LION Bioscience. iDEA™. Available from URL: http://www.lionbioscience.com [Accessed 2002 Jul 19]
14. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Technol Today 1998; 1: 387-93
15. Leahy DE, Duncan R, Ahr HJ, et al. Pharmacokinetics in early drug research: the report and recommendations of ECVAM Workshop 22. ATLA-Altern Lab Anim 1997; 25: 17-31
16. Pickett SD, McLay IM, Clark DE. Enhancing the hit-to-lead properties of lead optimization libraries. J Chem Inf Comput Sci 2000; 40: 263-72
17. Danelian E, Karlen A, Karlsson R, et al. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. J Med Chem 2000; 43: 2083-6
18. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41: 1007-10
19. Guo A, Hu P, Balimane PV, et al. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999; 289: 448-54
20. Salphati L, Childers K, Pan L, et al. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol 2001; 53: 1007-13
21. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-5
22. Fagerholm U, Lennernäs H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral-drug absorption. Eur J Pharm Sci 1995; 3: 247-53
23. Gorter E, Grendel F. On bimolecular layers of lipoids on the chromocytes of the blood. J Exp Med 1925; 41: 439-43
24. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175: 720-31
25. Somerharju P, Virtanen JA, Cheng KH. Lateral organisation of membrane lipids: the superlattice view. Biochim Biophys Acta 1999; 1440: 32-48
26. Alberts B, Bray D, Lewis J, et al. The plasma membrane. In: Alberts B, Bray D, Lewis J, et al., editors. Molecular biology of the cell. New York: Garland Publishing Inc., 1989: 275-340
27. Xiang T-X, Anderson BD. The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol 1994; 140: 111-22
28. Muranishi S. Absorption enhancers. Crit Rev Ther Drug Carrier Syst 1990; 7: 1-33
29. Stenberg P, Luthman K, Artursson P. Virtual screening of intestinal drug permeability. J Contr Release 2000; 65: 231-43
30. Collander R. The permeability of Nitella cells to non-electrolytes. Physiol Plant 1954; 7: 420-45
31. Shore PA, Brodie BB, Hogben CA. The gastric secretion of drugs: a pH-partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-9
32. Palm K, Ros J, Gråsjö J, et al. Effect of molecular charge on intestinal epithelial drug transport. J Pharmacol Exp Ther 1999; 291: 435-43
33. Marrink SJ, Berendsen HJC. Simulation of water transport through a lipid membrane. J Phys Chem 1994; 98: 4155-68
34. Bassolino D, Alper H, Stouch TR. Drug-membrane interactions studied by molecular dynamics simulation: size dependence of diffusion. Drug Des Discov 1996; 13: 135-41
35. Jacobs RE, White SE. The nature of the hydrophobic binding of small peptides at the bilayer interfaces: implications for the insertion of transbilayer helices. Biochemistry 1989; 28: 3421-37
36. Burton PS, Conradi RA, Hilgers AR, et al. The relationship between peptide structure and transport across epithelial cell monolayers. J Control Release 1992; 19: 87-98
37. Stenberg P, Luthman K, Artursson P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties [published erratum appears in Pharm Res 1999; 16: 1324]. Pharm Res 1999; 16: 205-12
38. Tieleman DP, Marrink SJ, Berendsen HJC. A computer perspective of membranes: molecular dynamics studies of lipid bilayer systems. Biochim Biophys Acta 1997; 1331: 235-70
39. Gallois L, Fiallo M, Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles: circular dichroism study. Biochim Biophys Acta 1998; 1370: 31-40
40. Krämer SD. Absorption prediction from physicochemical parameters. Pharm Sci Technol Today 1999; 2: 373-80
41. Clark DE, Pickett SD. Computational methods for the prediction of 'drug-likeness'. Drug Discov Today 2000; 5: 49-58
42. Lee K, Thakker DR. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 1999; 88: 680-7
43. Gan LS, Yanni S, Thakker DR. Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists. Pharm Res 1998; 15: 53-7
44. Stein WD. Transport and diffusion across cell membranes. Orlando: Academic Press Inc., 1986
45. Pappenheimer JR, Reiss KZ. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol 1987; 100: 123-36
46. Nellans HN. Paracellular intestinal transport: modulation of absorption. Adv Drug Deliv Rev 1991; 7: 339-64
47. Diamond JM. Twenty-first Bowditch lecture. The epithelial junction: bridge, gate, and fence. Physiologist 1977; 20: 10-8
48. Madara JL. Loosening tight junctions: lessons from the intestine. J Clin Invest 1989; 83: 1089-94
49. Artursson P, Ungell A-L, Löfroth J-E. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 1993; 10: 1123-9
50. Ungell A-L, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998; 87: 360-6
51. Lennernäs H. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is there time for reevaluation? Pharm Res 1995; 12: 1573-82
52. Karlsson J, Ungell A-L, Gråsjö J, et al. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur J Pharm Sci 1999; 9: 47-56
53. Tanaka H, Miyamoto KI, Morita K, et al. Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil-induced injury. Gastroenterology 1998; 114: 714-23
54. Lee VH. Membrane transporters. Eur J Pharm Sci 2000; 11: S41-50
55. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996; 13: 963-77
56. Baldwin SA, Mackay JR, Cass CE, et al. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 1999; 5: 216-24
57. Yang CY, Dantzig AH, Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharm Res 1999; 16: 1331-43
58. Meredith D, Boyd CAR. Structure and function of eukaryotic peptide transporters. Cell Mol Life Sci 2000; 57: 754-78
59. Liang R, Fei YJ, Prasad PD, et al. Human intestinal H+/peptide cotransporter: cloning, functional expression, and chromosomal localization. J Biol Chem 1995; 270: 6456-63
60. Covitz KMY, Amidon GL, Sadee W. Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry 1998; 37: 15214-21
61. Bolger MB, Haworth IS, Yeung AK, et al. Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J Pharm Sci 1998; 87: 1286-91
62. Fei YJ, Liu W, Prasad PD, et al. Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2. Biochemistry 1997; 36: 452-60
63. Chen XZ, Steel A, Hediger MA. Functional roles of histidine and tyrosine residues in the H+- peptide transporter PepT1. Biochem Biophys Res Commun 2000; 272: 726-30
64. Tame JRH. Ab initio phasing of a 4189-atom protein structure at 1.2 angstrom resolution. Acta Crystallogr D Biol Crystallogr 2000; 56: 1554-9
65. Döring F, Will J, Amasheh S, et al. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J Biol Chem 1998; 273: 23211-8
66. Börner V, Fei VJ, Hartrodt B, et al. Transport of amino acid aryl amides by the intestinal H+/peptide cotransport system, PEPT1. Eur J Biochem 1998; 255: 698-702
67. Bretschneider B, Brandsch M, Neubert R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 1999; 16: 55-61
68. Raeissi SD, Li JB, Hidalgo IJ. The role of an alpha-amino group on H+-dependent transepithelial transport of cephalosporins in Caco-2 cells. J Pharm Pharmacol 1999; 51: 35-40
69. Inui KI, Tomita Y, Katsura T, et al. H+ coupled active-transport of bestatin via the dipeptide transport-system in rabbit intestinal brush-border membranes. J Pharmacol Exp Ther 1992; 260: 482-6
70. Sugawara M, Huang W, Fei YL, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000; 89: 781-9
71. Han HK, de Vrueh RLA, Rhie JK, et al. 5′-amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998; 15: 1154-9
72. Sawada K, Terada T, Saito H, et al. Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 1999; 291: 705-9
73. Balimane PV, Sinko PJ. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv Drug Deliv Rev 1999; 39: 183-209
74. Tamai I, Nakanishi T, Nakahara H, et al. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J Pharm Sci 1998; 87: 1542-6
75. Meredith D, Temple CS, Guha N, et al. Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur J Biochem 2000; 267: 3723-8
76. Bailey PD, Boyd CAR, Bronk JR, et al. How to make drugs orally active: a substrate template for peptide transporter PepT1. Angew Chem Int Ed 2000; 39: 506-8
77. Hunter J, Hirst BH. Intestinal secretion of drugs: the role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997; 25: 129-57
78. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302
79. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000; 12: 3-12
80. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651-6
81. Taipalensuu J, Törnblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette family in normal human jejunum and in human intestinal epithelial Caco-2 cell monobyers. J Pharmacol Exp Ther 2001; 299: 164-70
82. Gotoh Y, Suzuki H, Kinoshita S, et al. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 2000; 292: 433-9
83. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40
84. Österberg T, Norinder U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10: 295-303
85. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998; 251: 252-61
86. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98
87. Makhey VD, Guo A, Norris DA, et al. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-7
88. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-8
89. Benet LZ, Izumi T, Zhang YC, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62: 25-31
90. Chiou WL, Chung SM, Wu TC. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 2000; 17: 903-5
91. Chiou WL, Chung SM, Wu TC. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm Res 2000; 17: 205-8
92. Sandström R, Karlsson A, Knutson L, et al. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998; 15: 856-62
93. Chung SM, Park EJ, Swanson SM, et al. Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model. Pharm Res 2001; 18: 544-7
94. Chiou WL, Chung SM, Wu TC, et al. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001; 39: 93-101
95. Daylight Chemical Information Systems Inc. SMILES home page. Available from URL: http://www.daylight.com/dayhtml/smiles/index.html [accessed 2002 Jul 19]
96. Raevsky OA. Hydrogen bond strength estimation by means of the HYBOT program package. In: van de Waterbeemd HBT, Folkers G, editors. Computer-assisted lead finding and optimization. Basel: Verlag Helvetica Chimica Acta, 1997: 367-78
97. Leo A, Jow PYC, Silipo C, et al. Calculation of hydrophobic constant (log P) from and of constants. J Med Chem 1975; 18: 865-8
98. Rekker RF. The hydrophobic fragmental constant. Vol. 1. Amsterdam: Elsevier Scientific Publishing Company, 1977
99. Hall LH, Mohney B, Kier LB. The electrotopological state: structure information at the atomic level for molecular graphs. J Chem Inf Comput Sci 1991; 31: 76-82
100. Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol 1971; 55: 379-400
101. Testa B, Carrupt P-A, Galliard P, et al. Lipophilicity in molecular modeling. Pharm Res 1996; 13: 335-43
102. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000; 43: 3714-7
103. Cruciani G, Crivori P, Carrupt PA, et al. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struct-Theochem 2000; 503: 17-30
104. Österberg T, Norinder U. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. J Chem Inf Comput Sci 2000; 40: 1408-11
105. Stenberg P, Norinder U, Luthman K, et al. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 2001; 44: 1927-37
106. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49
107. Ajay A, Walters WP, Murcko MA. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J Med Chem 1998; 41: 3314-24
108. Sadowski J, Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. J Med Chem 1998; 41: 3325-9
109. Gillet VJ, Willett P, Bradshaw J. Identification of biological activity profiles using substructural analysis and genetic algorithms. J Chem Inf Comput Sci 1998; 38: 165-79
110. Frimurer TM, Bywater R, Naerum L, et al. Improving the odds in discriminating 'drug-like' from 'non-drug-like' compounds. J Chem Inf Comput Sci 2000; 40: 1315-24
111. Wagener M, van Geerestein VJ. Potential drugs and nondrugs: prediction and identification of important structural features. J Chem Inf Comput Sci 2000; 40: 280-92
112. Kelder J, Grootenhuis PD, Bayada DM, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999; 16: 1514-9
113. Wang J, Ramnarayan K. Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. J Comb Chem 1999; 1: 524-33
114. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery: 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999; 1: 55-68
115. Xu J, Stevenson J. Drug-like index: a new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci 2000; 40: 1177-87
116. Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000; 43: 3867-77
117. Oprea TI. Property distribution of drug-related chemical databases. J Comput Aided Mol Des 2000; 14: 251-64
118. Palm K, Luthman K, Ungell A-L, et al. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996; 85: 32-9
119. Wessel MD, Jurs PC, Tolan JW, et al. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci 1998; 38: 726-35
120. Hansch C, Steward AR, Iwasa J. The correlation of localization rates of benzeneboronic acids in brain and tumor tissue with substituent constants. Mol Pharmacol 1965; 1: 87-92
121. Stein WD. The molecular basis of diffusion across cell membranes. New York: Academic Press Inc., 1967
122. van de Waterbeemd H, Camenisch G, Folkers G, et al. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant Struct-Act Relat 1996; 15: 480-90
123. Oprea TI, Gottfries J. Toward minimalistic modeling of oral drug absorption. J Mol Graph 1999; 17: 261-74
124. Raevsky OA, Fetisov VI, Trepalina EP, et al. Quantitative estimation of drug absorption in humans for passively transported compounds on the basis of their physico-chemical parameters. Quant Struct-Act Relat 2000; 19: 366-74
125. Platts JA, Abraham MH, Hersey A, et al. Estimation of molecular linear free energy relationship descriptors: 4. Correlation and prediction of cell permeation. Pharm Res 2000; 17: 1013-8
126. Martini LG, Avontuur P, George A, et al. Solubility parameter and oral absorption. Eur J Pharm Biopharm 1999; 48: 259-63
127. Norinder U, Österberg T. Theoretical calculation and prediction of drug transport processes using simple parameters and PLS statistics: the use of electrotopological state indices. J Pharm Sci 2001; 90: 1076-85
128. Österberg T, Norinder U. Prediction of drug transport processes using simple parameters and PLS statistics: the use of ACD/logP and ACD/ChemSketch descriptors. Eur J Pharm Sci 2001; 12: 327-37
129. Norinder U, Österberg T, Artursson P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 1999; 8: 49-56
130. Norinder U, Österberg T, Artursson P. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parametrization and PLS statistics. Pharm Res 1997; 14: 1785-90
131. Barlow D, Satoh T. The design of peptide analogues for improved absorption. J Control Release 1994; 29: 283-91
132. Ooi T, Oobatake M, Némethy G, et al. Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. Proc Natl Acad Sci U S A 1987; 84: 3086-90
133. Amidon GL, Yalkowsky SH, Anik ST, et al. Solubility of non-electrolytes in polar solvents: V. Estimation of the solubility of aliphatic monofunctional compounds in water using a molecular surface area approach. J Phys Chem 1975; 79: 2239-46
134. Palm K, Stenberg P, Luthman K, et al. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997; 14: 568-71
135. Palm K, Luthman K, Ungell A-L, et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem 1998; 41: 5382-92
136. Krarup LH, Christensen IT, Hovgaard L, et al. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations. Pharm Res 1998; 15: 972-8
137. Winiwarter S, Bonham NM, Ax F, et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters: a multivariate data analysis approach. J Med Chem 1998; 41: 4939-49
138. Stenberg P, Luthman K, Ellens H, et al. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm Res 1999; 16: 1520-6
139. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 1. prediction of intestinal absorption. J Pharm Sci 1999; 88: 807-14
140. Goodwin JT, Mao B, Vidmar TJ, et al. Strategies toward predicting peptide cellular permeability from computed molecular descriptors. J Pept Res 1999; 53: 355-69
141. van de Waterbeemd H, Kansy M. Hydrogen-bonding capacity and brain penetration. Chimia 1992; 46: 299-303
142. Augustijns PF, Brown SC, Willard DH, et al. Hydration changes implicated in the remarkable temperature- dependent membrane permeation of cyclosporin A. Biochemistry 2000; 39: 7621-30
143. US Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Available from URL: http://www.fda.gov/cder/guidance/3618fnl.pdf [Accessed 2002 Jul 19]
144. Bravi G, Wikel JH. Application of MS-WHIM descriptors: 3. Prediction of molecular properties. Quant Struct-Act Relat 2000; 19: 39-49
145. Ghuloum AM, Sage CR, Jain AN. Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules. J Med Chem 1999; 42: 1739-48
146. Segarra V, Lopez M, Ryder H, et al. Prediction of drug permeability based on grid calculations. Quant Struct-Act Relat 1999; 18: 474-81
147. Sjöberg P. MOLSURF: a generator of chemical descriptors for QSAR. In: van de Waterbeemd HBT, Folkers G, editors. Computer-assisted lead finding and optimization. Basel: Verlag Helvetica Chimica Acta, 1997: 81-92
148. Hansch C, Quinlan JE, Lawrence GL. The linear free-energy relationship between partition coefficients and the aqueous solubility of organic liquids. J Org Chem 1968; 33: 347-50
149. Amidon GL, Yalkowsky SH, Leung S. Solubility of non-electrolytes in polar solvents: II. Solubility of aliphatic alcohols in water. J Pharm Sci 1974; 63: 1858-66
150. Meylan WM, Howard PH, Boethling RS. Improved method for estimating water solubility from octanol/water partition coefficient. Environ Toxicol Chem 1996; 15: 100-6
151. Arakawa T, Timasheff SN. Mechanism of protein salting in and salting out by divalent cation salts: balance between hydration and salt binding. Biochemistry 1984; 23: 5912-23
152. Serajuddin ATM, Sheen P-C, Augustine MA. Common ion effect on solubility and dissolution rate of the sodium salt of an organic acid. J Pharm Pharmacol 1987; 39: 587-91
153. Khalil E, Najjar S, Sallam A. Aqueous solubility of diclofenac diethylamine in the presence of pharmaceutical additives: a comparative study with diclofenac sodium. Drug Dev Ind Pharm 2000; 26: 375-81
154. Miyazaki S, Oshiba M, Nadai T. Precaution on use of hydrochloride salts in pharmaceutical formulation. J Pharm Sci 1981; 70: 594-6
155. Arakawa T, Timasheff SN. Abnormal solubility behavior of β-lactoglobulin: salting-in by glycine and NaCl. Biochemistry 1987; 26: 5147-53
156. Charman WN, Porter CJH, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997; 86: 269-82
157. Hammad MA, Müller BW. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm 1998; 46: 361-7
158. Hammad MA, Müller BW. Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles. Drug Der Ind Pharm 1999; 25: 409-17
159. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-4
160. Kondo N, Iwao T, Masuda H, et al. Improved oral absorption of a poorly water-soluble drug, Ho-221, by wet-bead milling producing particles in submicron region. Chem Pharm Bull 1993; 41: 737-40
161. Kondo N, Iwao T, Kikuchi M, et al. Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals. Biol Pharmacol Bull 1993; 16: 796-800
162. Lund L. Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin. Eur J Clin Pharmacol 1974; 7: 119-24
163. Stella VJ, Martodihardjo S, Rao VM. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs. J Pharm Sci 1999; 88: 775-9
164. Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997; 86: 450-4
165. Abraham MH, Lee J. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. J Pharm Sci 1999; 88: 868-80
166. Huuskonen J, Salo M, Taskinen J. Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J Chem Inf Comput Sci 1998; 38: 450-6
167. Mitchell BE, Jurs PC. Prediction of aqueous solubility of organic compounds from molecular structure. J Chem Inf Comput Sci 1998; 38: 489-96
168. Huuskonen J, Rantanen J, Livingstone D. Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. Eur J Med Chem 2000; 35: 1081-8
169. Yalkowsky SH, Valvani SC. Solubility and partitioning: I. Solubility of non-electrolytes in water. J Pharm Sci 1980; 69 (8): 912-22
170. Yalkowsky SH. Solubility and partitioning: V. Dependence of solubility on melting point. J Pharm Sci 1981; 70 (8): 971-3
171. Yalkowsky SH, Pinal R, Banerjee S. Water solubility: a critique of the solvatochromic approach. J Pharm Sci 1988; 77 (1): 74-7
172. Myrdal PB, Manka AM, Yalkowsky SH. Aquafac: 3. Aqueous functional group activity coefficients; application to the estimation of aqueous solubility. Chemosphere 1995; 30: 1619-37
173. Hildebrand JC, Scott RL. The solubility of nonelectrolytes. New York: Reinhold Publishing Corporation, 1950
174. Beerbower A, Kaye LA, Pattison DA. Picking the right elastomet to fit your fluids. Chem Eng 1967; 74: 118-28
175. Hansen CM. The three dimensional solubility parameter: key to paint component affinities: I. solvents, plasticizers, polymers, and resins. J Paint TechnoI 1967; 39: 104-17
176. Bagley EB, Nelson TP, Scigliano JM. Three-dimensional solubility parameters and their relationship to internal pressure measurements in polar and hydrogen bonding solvents. J Paint Technol 1971; 43: 35-42
177. Kamlet MJ, Abboud J-LM, Abraham MH, et al. Linear solvation energy relationships: 23. A comprehensive collection of the solvatochromic parameters, π*, α, and β, and some methods for simplifying the generalized solvatochromic equation. J Org Chem 1983; 48: 2877-87
178. Kamlet MJ, Doherty RM, Abboud J-LM, et al. Linear solvation energy relationships: 36. Molecular properties governing solubilities of organic nonelectrolytes in water. J Pharm Sci 1986; 75: 338-49
179. Kamlet MJ, Doherty RM, Fiserova-Bergerova V, et al. Solubility properties in biological media 9: prediction of solubility and partition of organic nonelectrolytes in blood and tissue from solvatochromic parameters. J Pharm Sci 1987; 76: 14-7
180. Jorgensen WL, Duffy EM. Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 2000; 10: 1155-8
181. Sirius Analytical Instruments Ltd. Absolv solute property prediction version 1.2. Available from URL: http://www.siriusanalytical.com/absolv.htm [Accessed 2002 Jul 19]
182. Bodor N, Harget A, Huang M-J. Neural network studies: 1. Estimation of the aqueous solubility of organic compounds. J Am Chem Soc 1991; 113: 9480-3
183. Bodor N, Huang M-J. A new method for the estimation of the aqueous solubility of organic compounds. J Pharm Sci 1992: 81: 954-60
184. Nelson TM, Jurs PC. Prediction of aqueous solubility of organic compounds. J Chem Inf Comput Sci 1994; 34: 601-9
185. Sutter JM, Jurs PC. Prediction of aqueous solubility for a diverse set of heteroatom-containing organic compounds using a quantitative structure-property relationship. J Chem Inf Comput Sci 1996; 36: 100-7